What is HC Wainwright’s Forecast for PVLA Q4 Earnings?

Palvella Therapeutics (NASDAQ:PVLA) – Analysts at HC Wainwright issued their Q4 2024 EPS estimates for Palvella Therapeutics in a note issued to investors on Thursday, December 26th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.39) for the quarter. HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. HC Wainwright also issued estimates for Palvella Therapeutics’ Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.11) EPS, FY2025 earnings at ($3.93) EPS, FY2026 earnings at ($4.12) EPS, FY2027 earnings at ($4.38) EPS and FY2028 earnings at ($2.62) EPS.

Separately, Cantor Fitzgerald started coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They issued an “overweight” rating on the stock.

Palvella Therapeutics Stock Up 1.0 %

Shares of Palvella Therapeutics stock opened at $12.00 on Friday. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $22.32. The firm has a market capitalization of $15.84 million, a PE ratio of -0.99 and a beta of 0.61.

Insiders Place Their Bets

In other Palvella Therapeutics news, Director George M. Jenkins purchased 4,000 shares of the company’s stock in a transaction on Wednesday, December 18th. The shares were bought at an average cost of $12.93 per share, with a total value of $51,720.00. Following the transaction, the director now directly owns 180,671 shares in the company, valued at approximately $2,336,076.03. This represents a 2.26 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 6.39% of the company’s stock.